TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00704314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 80 mg Simvastatin daily for 8 weeks
Study: NCT04644835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Energy Shock Wave Treatment
Description: The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: The patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
Study: NCT00704314

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was identical in appearance and was provided by the same manufacturer
Study: NCT00662519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta (Pegylated)
Description: Subjects will receive 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
Study: NCT04561375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: 30 µg tablet of sublingual sufentanil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: 50 µg fentanyl
Study: NCT03216018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention program: In Favor of Resilient Self
Description: Prevention program: In Favor of Resilient Self
Study: NCT01540773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid supplement
Description: An orally administered supplement of the proprietary amino acid derivative

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A non-active orally administered supplement of the proprietary amino acid derivative
Study: NCT01989962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E4E intervention
Description: The E4E intervention consists of a one-day face-to-face workshop and a series of follow-up online learning modules. Workshop and online content will be tailored to meet individual participants' needs determined by a pre-program needs assessment. E4E intervention will emphasize clinically based case scenarios and are designed to reinforce the workshop concepts and stimulate reflection. Participating family physicians will attend the workshop and engage in reflections and small-group interactions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: E4E intervention
Description: The E4E intervention consists of a one-day face-to-face workshop and a series of follow-up online learning modules. Workshop and online content will be tailored to meet individual participants' needs determined by a pre-program needs assessment. E4E intervention will emphasize clinically based case scenarios and are designed to reinforce the workshop concepts and stimulate reflection. Participating family physicians will attend the workshop and engage in reflections and small-group interactions.
Study: NCT04326114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory training device
Description: Inspiratory training by a Power-breath device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory training device
Description: Expiratory training a Winner-flow device
Study: NCT03996148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil, Propofol, and Desflurane
Description: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Propofol - titratable; initial starting dose 75 mcg/kg/min Desflurane 0.5 MAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil, Dexmedetomidine, and Desflurane
Description: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Dexmedetomidine - titratable; initial starting dose 0.5 mcg/kg/hr Desflurane 0.5 MAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil and Desflurane
Description: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Desflurane - titratable
Study: NCT03462849

Intervention type: OTHER
Group type: OTHER
Intervention: increase in positive end expiratory pressure
Description: increase in positive end expiratory pressure from 5 to 10 then 15 cmH2O then at the value for trans pulmonary end expiratory pressure amounting to 3 cmH2O

Intervention type: OTHER
Group type: OTHER
Intervention: increase in positive end expiratory pressure
Description: increase in positive end expiratory pressure from 5 to 10 then 15 cmH2O then at the value for trans pulmonary end expiratory pressure amounting to 3 cmH2O
Study: NCT03916510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enadenotucirev
Description: Enadenotucirev is a live replicating oncolytic adenovirus; it is considered a BioSafety Level 1 (BSL-1) infectious substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil. Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50 Gy/25#
Study: NCT00662519

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed Meal Tolerance Test (MMTT)
Description: This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mixed Meal Tolerance Test (MMTT)
Description: This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test
Description: HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood test
Description: HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DNA Test
Description: The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DNA Test
Description: The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.
Study: NCT02327312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stents
Description: Two Trabecular meshwork Micro-Bypass stents into the study eye

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser Trabeculoplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Trabeculoplasty
Study: NCT00198367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-Gemzar

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-Navelbine-Radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin-Taxol-Radiotherapy
Study: NCT05316818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI Protocol
Description: Triplet chemotherapy regimen consists from active three cytotoxic agents aiming to improve outcomes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOXIRI Protocol
Description: Triplet chemotherapy regimen consists from active three cytotoxic agents aiming to improve outcomes
Study: NCT00535444

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parish nurse visit
Description: One visit with the parish nurse in 2 weeks
Study: NCT03561246

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incline treadmill walking
Description: Those with a Pp \<0.47 or \>0.53 will undergo INCLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decline treadmill walking
Description: Those with a Pp \<0.47 or \>0.53 will undergo DECLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Level Treadmill (Control)
Description: Those with a Pp \<0.47 or \>0.53 will undergo LEVEL training during which individuals will walk for 15 minutes at a 0-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
Study: NCT02820558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Substance P

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Substance P

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Substance P

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Substance P
Study: NCT01879189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Cancer Screening Decision Aid
Description: The intervention will include access to the personal decision aid tool for patients in the intervention arm of the study, determined by the randomized physician schedule and the patient's appointment time.
Study: NCT02561780

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Curriculum
Description: A mental health educational resource delivered in the classroom by trained educators

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Curriculum
Description: A mental health educational resource delivered in the classroom by trained educators
Study: NCT04295382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Software Application
Description: A software application targeting suicidal ideation via interactive exercises.
Study: NCT02538341

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herpes Zoster (HZ) Vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04434742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex interventions
Description: An advanced practice nurse (APN) from a hospital discharge team visited them to familiarize him/herself with their condition and prepare a discharge plan. A face-to-face or telephone call handover between the APN and the project nurse case manager (NCM) was performed before the client was discharged. The past and current medical conditions, medical and nursing management, and follow-up appointments were discussed. After discharge home, the NCM, functioning as the leader of health-social care team, conducted the initial assessment in the first home visit to identify the client's health and social problems within one week of discharge. Community workers, supervised by both the nurse case manager and social worker, provided telephone follow-up and subsequent home visits to monitor the client's progress and provide support when necessary.
Study: NCT02561780

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eLearning Follow-up
Description: An online mental health education module that students access individually
Study: NCT04434742

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Social call was given to this group.
Study: NCT03548857

Intervention type: OTHER
Intervention: Lung transplantation
Description: Single or double lung transplantation in patients with COPD
Study: NCT00611559

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ penta
Description: Subjects received a booster dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa
Description: Subjects received a booster dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa
Description: Subjects received a booster dose
Study: NCT04870749

Intervention type: DIAGNOSTIC_TEST
Intervention: IPP,IPSS,VPSS
Description: Prostate volume, IPSS, VPSS and IPP were determined after urological examinations of the patients.
Study: NCT04338399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib & Paclitaxel
Description: Investigation drug plus paclitaxel
Study: NCT00186888

Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiation
Description: 44-46 Gy administered using standard practices , limiting dose to normal tissues to subjects with recurrent or progressive disease not considered controllable with focal treatments, Stratum B subjects with suspected active disease after completing therapy, or patients considered to have high-risk disease.

Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiation
Description: 44-46 Gy administered using standard practices , limiting dose to normal tissues to subjects with recurrent or progressive disease not considered controllable with focal treatments, Stratum B subjects with suspected active disease after completing therapy, or patients considered to have high-risk disease.

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine and Topotecan
Description: (Stratum B subjects receive two up-front courses of vincristine and topotecan, given in 21-day intervals, then those who respond receive 3 additional courses (courses 5, 8, and 11) after the window. Dosages are the same for both window and subsequent courses: Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Topotecan: TSE of 140 ± 20 ng/ml\*hr, daily for 5 consecutive days, infused over 30 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine + Carboplatin + Etoposide
Description: Stratum B patients that do not respond to window receive 6 courses of this combination.~Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, \< 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3

Intervention type: DRUG
Group type: OTHER
Intervention: vincristine, cyclophosphamide, and doxorubicin
Description: (High risk Stratum C patients in courses 2, 4, and 6 after enucleation, intermediate risk stratum C patients for four consecutive courses after enucleation) Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Cyclophosphamide: \< 12 months of age: 40 mg/kg i.v. day 1, ≥ 12 months of age: 1,200 mg/m2 i.v. day 1, MESNA 200 mg/m2 at 0, 3, 6, and 9 hours Doxorubicin \< 12 months of age: 1.5 mg/kg i.v. day 1, ≥ 12 months of age: 45 mg/m2 i.v. day 1
Study: NCT03874195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to PCforMe for review
Description: Intervention Arm subjects will receive access to PCforMe.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to three nationally-recognized Palliative Care websites for review
Description: Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care
Study: NCT04493593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SilverCloud
Description: 'Space for Sleep' is a seven-module online CBT-based intervention for sleep. The structure and content of the programme modules follow evidence-based CBT principles for insomnia. Each module is structured to incorporate introductory quizzes. videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.~As per normal service provision, each participant will be assigned a clinician (PWP) who will monitor participants' progress through the program. Every one to two weeks, the PWP will login and review participants' progress, leaving feedback for them and responding to the work they have completed.
Study: NCT04059874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donafenib tablets
Description: donafenib tablets 100mg qd dose group and donafenib tablets 100mg bid dose group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donafenib tablets
Description: donafenib tablets 100mg qd dose group and donafenib tablets 100mg bid dose group
Study: NCT04338399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buparlisib & Paclitaxel
Description: Investigation drug plus paclitaxel
Study: NCT01954836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: initial fasting
Description: modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the first half of scheduled 4 or 6 chemotherapy cycles

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Secondary fasting
Description: modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the second half of scheduled 4 or 6 chemotherapy cycles
Study: NCT01952288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 40 mg/day for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo comparator
Study: NCT01603212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.~Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alpha-2b
Description: 5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
Study: NCT05941676

Intervention type: DIAGNOSTIC_TEST
Intervention: Tumour immunoprofile evaluation
Description: Tumour immunoprofile evaluation will be performed in patients with head and neck cancer.
Study: NCT00186888

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine, Carboplatin and Etoposide
Description: High risk Stratum C patients in courses 1, 3, and 5 after enucleation: Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, \< 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periocular carboplatin
Description: Periocular (subtenon) carboplatin 20 mg, one injection, in courses 5, 8, and 11 in patients responding to the VT window, and in courses 1, 3, and 6 of VCE in patients not responding to the VT window, when active vitreous disease is present. Carboplatin 20 mg will be diluted in 2 mL of NS or D5W and given by subtenon administration while the patient is under general anesthesia.
Study: NCT04212546

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic test drink
Description: In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g inulin + Lactobacillus casei431 \[\>106cfu/mL\] per day for 21 days with their habitual diet.
Study: NCT00186888

Intervention type: OTHER
Group type: OTHER
Intervention: G-CSF
Description: G-CSF (5 mcg/kg/day), will be administered starting 24-36 hours after the completion of each course of chemotherapy, for 7 to 10 days, until ANC is \> 2,000/mL in one occasion after the expected nadir.

Intervention type: OTHER
Group type: OTHER
Intervention: G-CSF
Description: G-CSF (5 mcg/kg/day), will be administered starting 24-36 hours after the completion of each course of chemotherapy, for 7 to 10 days, until ANC is \> 2,000/mL in one occasion after the expected nadir.
Study: NCT04212546

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Description: In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g maltodextrin per day for 21 days with their habitual diet.
Study: NCT03529890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Experimental intervention:~Immunotherapy with 4 cycles of Nivolumab: 240 mg intravenously every 2 weeks, starting one week before radiotherapy (week1, d1), last infusion on week 7, d1
Study: NCT03592732

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample
Study: NCT03529890

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy of the pelvis
Description: Neoadjuvant radiation therapy of pelvis with 45+5,4 Gy for 6 weeks: 28 x 1.8 Gy including a boost of bladder with 5.4 Gy, starting with week 2 (d1)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical cystectomy with standardized pelvic lymphadenectomy
Description: Radical cystectomy with standardized bilateral pelvic lymphadenectomy: performed between week 11 - 15 (Aim: week 13)